Immune checkpoint was another important target for glioma treatment and some immunotherapy drugs had entered clinical trials, inhibition of PD‐L1, CTLA4, Indoleamine 2,3‐dioxygenase (IDO) was included.67 This evidence concerns the gene IDO2 and glioma.